



C4X Discovery

A new dimension in drug discovery

C4X Discovery wins Smart grant from UK's innovation agency, Innovate UK

Manchester and London, UK, 30 March, 2015 – C4X Discovery (AIM: C4XD), a leader in rational drug discovery and design, today announced that it has won a further grant from the UK's innovation agency, Innovate UK. This Smart award is the second Innovate UK grant C4XD has won recently in the area of type 2 diabetes, following our success with the Biomedical Catalyst, announced in July 2014.

The Smart award will cover C4XD's work to validate a potential target for the treatment of type 2 diabetes. Positive results from this would justify a subsequent C4XD drug discovery programme which could lead to the creation of a new class of type 2 diabetes medicines. The American Diabetes Association estimates the annual cost of the disease to be \$245bn; type 2 diabetes comprises approximately 90 per cent of the patient population.

C4XD has the only technology in the world that can generate accurate, experimentally-derived dynamic solution 3D structures of drug molecules in just a matter of days, helping to accelerate product development. Our conformational insights can be used in conjunction with existing technologies for rational drug design and can make a particularly high impact when protein crystallography is not routinely available, as is the case for GPCRs (G-protein-coupled receptors, such as orexin receptors) and ion channels.

Piers Morgan, CEO of C4XD, said "We are excited by this success. This second grant from the UK's innovation agency, Innovate UK, shows their recognition of C4XD's ability to bring our game-changing technology to play in areas which have been highly challenging for traditional drug development strategies."

--ENDS--

For further information please contact:

C4X Discovery Ltd

Piers Morgan, CEO

07912 293832

Zeus Capital

Ross Andrews/Dan Bate

0161 831 1512

Dominic Wilson

020 7533 7727

FTI Consulting

Matthew Cole / Ben Atwell / Matthew Moss,

020 3727 1000

About C4X Discovery Ltd

C4XD is a Manchester-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since C4XD's NMR technology shows what shapes active molecules prefer to adopt, it provides high-quality templates for drug discovery and design, and valuable conformational information for drug candidate optimisation. In addition, the data is generated faster and more reliably than standard techniques such as X-ray co-crystallography or molecular modelling. C4XD is using its technology in collaboration with the pharmaceutical industry and to build its own proprietary pipeline of high-value therapeutic candidates. For additional information please go to:

www.c4xdiscovery.com

About Innovate UK

Innovate UK is the new name for the Technology Strategy Board – the UK's innovation agency. Taking a new idea to market is a challenge. Innovate UK funds, supports and connects innovative businesses through a unique mix of people and programmes to accelerate sustainable economic growth. For further information visit:

<https://www.gov.uk/government/organisations/innovate-uk>

Managed by Innovate UK, the Smart scheme offers funding to small and medium-sized enterprises (SMEs) to engage in R&D projects in the strategically important areas of science, engineering and technology, from which successful new products, processes and services could emerge.

<https://www.gov.uk/innovation-apply-for-a-funding-award#find-an-innovation-funding-programme>